Prostate cancer SubtyPINg BiomarKers and outcome: Is clarity EmERGing?

Clinical Cancer Research

Volumn 20, Issue 18, 2014, Pages 4733-4736

  Smith, Steven C ^a,b,c   Tomlins, Scott A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; ERG PROTEIN, HUMAN; SPINK1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

BIOSYNTHESIS; HUMAN; MALE; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR;

BIOMARKERS, TUMOR; CARRIER PROTEINS; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS;

EID: 84907439309     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0818     Document Type: Article

References (16)

1. Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn SP, Kunz L, et al. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res 2014;20:4904-11.
2. Brenner JC, Chinnaiyan AM, Tomlins SA. ETS fusion genes in prostate cancer. In: Tindall DJ, editor. Prostate cancer: biochemistry, molecular biology and genetics. New York, NY: Springer New York; 2013. p. 139-83.
3. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008;13:519-28.
4. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1, and MED12 mutations in prostate cancer. Nat Genet 2012; 44:685-9.
5. Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, Clark J, et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 2009;103: 1256-69.
6. Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S, et al. SPINK1 expression is tightly linked to 6q15-and 5q21-deleted ERGfusion negative prostate cancers but unrelated to PSA recurrence. Prostate 2013;73:1690-8.
7. Lippolis G, Edsjo A, Stenman UH, Bjartell A. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells. Prostate Cancer Prostatic Dis 2013;16:145-50.
8. Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, et al. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol 2013;26:835-48.
9. Minner S, Gartner M, Freudenthaler F, Bauer M, Kluth M, Salomon G, et al. Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol 2013;26:106-16.
10. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010;13:228-37.
11. Kunju LP, Carskadon S, Siddiqui J, Tomlins SA, Chinnaiyan AM, Palanisamy N. Novel RNA hybridization method for the in situ detection of ETV1, ETV4 and ETV5 gene fusions in prostate cancer. Appl Immunohistochem Mol Morphol. In press.
12. Smith SC, Palanisamy N, Zuhlke KA, Johnson AM, Siddiqui J, Chinnaiyan AM, et al. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. Am J Surg Pathol 2014;38: 615-26.
13. Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castrationresistant prostate cancer. Histopathology 2012;60:645-52.
14. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, et al. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol 2007;52:1670-9.
15. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramaki OR, et al. Association of SPINK1 expression and TMPRSS2: ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010;16:2845-51.
16. Wang C, Wang L, Su B, Lu N, Song J, Yang X, et al. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer. Prostate 2014; 74:689-701.